PF-04971729

Research use only, not for human use.

A potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2.

A potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2; shows >2000-fold selectivity over hSGLT1; demonstrates robust urinary glucose excretion in rats and an excellent preclinical safety profile.Diabetes Phase 3 Clinical(In Vitro):Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro.(In Vivo):Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats.

——

——

Ertugliflozin | MK-8835 | PF-4971729

GPCR/G Protein

SGLT

SGLT2

Metabolic Disease

Diabetes

1210344-57-2

436.8827

C22H25ClO7

>98% (HPLC)

DMSO: ≥ 46 mg/mL

O[C@@H]1[C@](O2)(CO)CO[C@]2(C3=CC=C(Cl)C(CC4=CC=C(C=C4)OCC)=C3)[C@H](O)[C@H]1O

β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-

(-20℃)

With Ice Pack

≥ 2 years